Dual effect of radiotherapy related concomitant cardiovascular diseases in non-small cell lung cancer.
cardiac deaths
epidemiology
mortality
non-small cell lung cancer
radiation therapy
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
revised:
12
05
2022
received:
15
04
2022
accepted:
28
05
2022
pubmed:
28
6
2022
medline:
1
2
2023
entrez:
27
6
2022
Statut:
ppublish
Résumé
Nowadays, cancer and cardiac diseases are two of the most causes of death, so cancer treatment-related cardiac death cannot be ignored. For lung cancer, chest radiotherapy (RT) is essential, but the related cardiotoxicity has not been fully studied. We reviewed the data of 11,455 patients with non-small cell lung cancer (NSCLC) from the Surveillance, Epidemiology, and End Results database from 2001 to 2015. The change trend for concomitant cardiovascular diseases (CVD)-specific death was calculated and graphically demonstrated. Univariate and multivariate analyses for survival were performed using Cox risk regression model. In our analysis, the overall incidence and mortality from NSCLC declined, but CVD-specific death increased. Both chemoradiotherapy and radiotherapy alone played a significant role in CVD-specific death. Analyzed longitudinally from diagnosis, we found that the effect of RT in CVD-specific death increased continuously over the third years and the hazard ratio for CVD-specific death was 1.386 times between RT and non-RT group (HR = 1.386, 95% CI 1.322-1.452; p < 0.0001). On the other hand, RT played a protective role in CVD-specific death before the second years, especially in recent years from 2013 to 2015 (HR = 0.843, 95% CI 0.740-0.959; p = 0.009). Although the mortality from NSCLC decreased, but radiotherapy-related CVD-specific mortality cannot be ignored. In the long-term over 3 years, RT significantly promoted CVD-specific death. However, RT turned to be a protective role in the short-term within 2 years. In clinical practice, we need to comprehensively consider the dual effects of radiotherapy on the side effect of heart.
Sections du résumé
BACKGROUND
Nowadays, cancer and cardiac diseases are two of the most causes of death, so cancer treatment-related cardiac death cannot be ignored. For lung cancer, chest radiotherapy (RT) is essential, but the related cardiotoxicity has not been fully studied.
METHODS
We reviewed the data of 11,455 patients with non-small cell lung cancer (NSCLC) from the Surveillance, Epidemiology, and End Results database from 2001 to 2015. The change trend for concomitant cardiovascular diseases (CVD)-specific death was calculated and graphically demonstrated. Univariate and multivariate analyses for survival were performed using Cox risk regression model.
RESULTS
In our analysis, the overall incidence and mortality from NSCLC declined, but CVD-specific death increased. Both chemoradiotherapy and radiotherapy alone played a significant role in CVD-specific death. Analyzed longitudinally from diagnosis, we found that the effect of RT in CVD-specific death increased continuously over the third years and the hazard ratio for CVD-specific death was 1.386 times between RT and non-RT group (HR = 1.386, 95% CI 1.322-1.452; p < 0.0001). On the other hand, RT played a protective role in CVD-specific death before the second years, especially in recent years from 2013 to 2015 (HR = 0.843, 95% CI 0.740-0.959; p = 0.009).
CONCLUSIONS
Although the mortality from NSCLC decreased, but radiotherapy-related CVD-specific mortality cannot be ignored. In the long-term over 3 years, RT significantly promoted CVD-specific death. However, RT turned to be a protective role in the short-term within 2 years. In clinical practice, we need to comprehensively consider the dual effects of radiotherapy on the side effect of heart.
Identifiants
pubmed: 35754191
doi: 10.1002/cam4.4948
pmc: PMC9883436
doi:
Types de publication
Review
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1025-1034Informations de copyright
© 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Pharmacol Res. 2019 Mar;141:357-365
pubmed: 30641276
Cancer Epidemiol Biomarkers Prev. 2015 Jul;24(7):1079-85
pubmed: 26065838
Thorax. 2019 Jul;74(7):700-704
pubmed: 30420406
Front Oncol. 2020 Oct 22;10:572380
pubmed: 33194672
Ann Thorac Surg. 2017 Jul;104(1):303-307
pubmed: 28433225
Cancer Med. 2023 Jan;12(2):1025-1034
pubmed: 35754191
J Clin Oncol. 2017 Mar 10;35(8):893-911
pubmed: 27918725
Ann Oncol. 2020 Feb;31(2):171-190
pubmed: 31959335
Lung Cancer. 2015 Apr;88(1):85-93
pubmed: 25704956
J Am Coll Cardiol. 2019 Jun 18;73(23):2976-2987
pubmed: 31196455
Cancer. 2005 Sep 15;104(6):1129-37
pubmed: 16080176
Ann Oncol. 2013 May;24(5):1312-9
pubmed: 23300016
J Thorac Cardiovasc Surg. 2002 Feb;123(2):280-7
pubmed: 11828287
J Appl Clin Med Phys. 2014 Sep 08;15(5):4898
pubmed: 25207575
Int J Radiat Oncol Biol Phys. 2014 Jan 1;88(1):167-74
pubmed: 24331664
Cancer Control. 2007 Jan;14(1):13-22
pubmed: 17242667
J Clin Oncol. 2017 Jan;35(1):56-62
pubmed: 28034064
Ann Oncol. 2017 May 1;28(5):1084-1089
pubmed: 28453703
J Clin Oncol. 2018 Jun 20;36(18):1813-1822
pubmed: 29293386
Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):1442-57
pubmed: 20934273
Int J Radiat Oncol Biol Phys. 2019 Oct 1;105(2):346-355
pubmed: 31175902
Radiother Oncol. 2020 Nov;152:183-188
pubmed: 31740185
Rep Pract Oncol Radiother. 2020 Jan-Feb;25(1):13-19
pubmed: 31762693
Front Cardiovasc Med. 2017 Oct 26;4:66
pubmed: 29124057
Int J Cardiol. 2021 May 1;330:186-193
pubmed: 33581175
Nat Commun. 2020 Apr 24;11(1):2011
pubmed: 32332714